Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Changes in the distribution of etiologies of cirrhosis among patients referred for liver transplantation over 11 years in Iran.

Mohagheghi S, Khajehahmadi Z, Nikeghbalian S, Alavian SM, Doosti-Irani A, Khodadadi I, Karimi J, Sharafi H, Tavilani H.

Eur J Gastroenterol Hepatol. 2019 Oct 30. doi: 10.1097/MEG.0000000000001590. [Epub ahead of print]

PMID:
31688307
2.

Drug use and risk behaviour profile, and the prevalence of HIV, hepatitis C and hepatitis B among people with methamphetamine use in Iran.

Moradi G, Hajarizadeh B, Rahmani K, Mohamadi-Bolbanabad A, Darvishi S, Zareie B, Zavareh FA, Sharafi H, Alavian SM, Ramazani R, Eftekhar M, Radfar SR, Piroozi B, Gouya MM.

Int J Drug Policy. 2019 Nov;73:129-134. doi: 10.1016/j.drugpo.2019.09.018. Epub 2019 Oct 22.

PMID:
31654935
3.

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study.

Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, Abdel-Rahman O, Abdelalim A, Abdoli A, Abdollahpour I, Abdulle ASM, Abebe ND, Abraha HN, Abu-Raddad LJ, Abualhasan A, Adedeji IA, Advani SM, Afarideh M, Afshari M, Aghaali M, Agius D, Agrawal S, Ahmadi A, Ahmadian E, Ahmadpour E, Ahmed MB, Akbari ME, Akinyemiju T, Al-Aly Z, AlAbdulKader AM, Alahdab F, Alam T, Alamene GM, Alemnew BTT, Alene KA, Alinia C, Alipour V, Aljunid SM, Bakeshei FA, Almadi MAH, Almasi-Hashiani A, Alsharif U, Alsowaidi S, Alvis-Guzman N, Amini E, Amini S, Amoako YA, Anbari Z, Anber NH, Andrei CL, Anjomshoa M, Ansari F, Ansariadi A, Appiah SCY, Arab-Zozani M, Arabloo J, Arefi Z, Aremu O, Areri HA, Artaman A, Asayesh H, Asfaw ET, Ashagre AF, Assadi R, Ataeinia B, Atalay HT, Ataro Z, Atique S, Ausloos M, Avila-Burgos L, Avokpaho EFGA, Awasthi A, Awoke N, Ayala Quintanilla BP, Ayanore MA, Ayele HT, Babaee E, Bacha U, Badawi A, Bagherzadeh M, Bagli E, Balakrishnan S, Balouchi A, Bärnighausen TW, Battista RJ, Behzadifar M, Behzadifar M, Bekele BB, Belay YB, Belayneh YM, Berfield KKS, Berhane A, Bernabe E, Beuran M, Bhakta N, Bhattacharyya K, Biadgo B, Bijani A, Bin Sayeed MS, Birungi C, Bisignano C, Bitew H, Bjørge T, Bleyer A, Bogale KA, Bojia HA, Borzì AM, Bosetti C, Bou-Orm IR, Brenner H, Brewer JD, Briko AN, Briko NI, Bustamante-Teixeira MT, Butt ZA, Carreras G, Carrero JJ, Carvalho F, Castro C, Castro F, Catalá-López F, Cerin E, Chaiah Y, Chanie WF, Chattu VK, Chaturvedi P, Chauhan NS, Chehrazi M, Chiang PP, Chichiabellu TY, Chido-Amajuoyi OG, Chimed-Ochir O, Choi JJ, Christopher DJ, Chu DT, Constantin MM, Costa VM, Crocetti E, Crowe CS, Curado MP, Dahlawi SMA, Damiani G, Darwish AH, Daryani A, das Neves J, Demeke FM, Demis AB, Demissie BW, Demoz GT, Denova-Gutiérrez E, Derakhshani A, Deribe KS, Desai R, Desalegn BB, Desta M, Dey S, Dharmaratne SD, Dhimal M, Diaz D, Dinberu MTT, Djalalinia S, Doku DT, Drake TM, Dubey M, Dubljanin E, Duken EE, Ebrahimi H, Effiong A, Eftekhari A, El Sayed I, Zaki MES, El-Jaafary SI, El-Khatib Z, Elemineh DA, Elkout H, Ellenbogen RG, Elsharkawy A, Emamian MH, Endalew DA, Endries AY, Eshrati B, Fadhil I, Fallah V, Faramarzi M, Farhangi MA, Farioli A, Farzadfar F, Fentahun N, Fernandes E, Feyissa GT, Filip I, Fischer F, Fisher JL, Force LM, Foroutan M, Freitas M, Fukumoto T, Futran ND, Gallus S, Gankpe FG, Gayesa RT, Gebrehiwot TT, Gebremeskel GG, Gedefaw GA, Gelaw BK, Geta B, Getachew S, Gezae KE, Ghafourifard M, Ghajar A, Ghashghaee A, Gholamian A, Gill PS, Ginindza TTG, Girmay A, Gizaw M, Gomez RS, Gopalani SV, Gorini G, Goulart BNG, Grada A, Ribeiro Guerra M, Guimaraes ALS, Gupta PC, Gupta R, Hadkhale K, Haj-Mirzaian A, Haj-Mirzaian A, Hamadeh RR, Hamidi S, Hanfore LK, Haro JM, Hasankhani M, Hasanzadeh A, Hassen HY, Hay RJ, Hay SI, Henok A, Henry NJ, Herteliu C, Hidru HD, Hoang CL, Hole MK, Hoogar P, Horita N, Hosgood HD, Hosseini M, Hosseinzadeh M, Hostiuc M, Hostiuc S, Househ M, Hussen MM, Ileanu B, Ilic MD, Innos K, Irvani SSN, Iseh KR, Islam SMS, Islami F, Jafari Balalami N, Jafarinia M, Jahangiry L, Jahani MA, Jahanmehr N, Jakovljevic M, James SL, Javanbakht M, Jayaraman S, Jee SH, Jenabi E, Jha RP, Jonas JB, Jonnagaddala J, Joo T, Jungari SB, Jürisson M, Kabir A, Kamangar F, Karch A, Karimi N, Karimian A, Kasaeian A, Kasahun GG, Kassa B, Kassa TD, Kassaw MW, Kaul A, Keiyoro PN, Kelbore AG, Kerbo AA, Khader YS, Khalilarjmandi M, Khan EA, Khan G, Khang YH, Khatab K, Khater A, Khayamzadeh M, Khazaee-Pool M, Khazaei S, Khoja AT, Khosravi MH, Khubchandani J, Kianipour N, Kim D, Kim YJ, Kisa A, Kisa S, Kissimova-Skarbek K, Komaki H, Koyanagi A, Krohn KJ, Bicer BK, Kugbey N, Kumar V, Kuupiel D, La Vecchia C, Lad DP, Lake EA, Lakew AM, Lal DK, Lami FH, Lan Q, Lasrado S, Lauriola P, Lazarus JV, Leigh J, Leshargie CT, Liao Y, Limenih MA, Listl S, Lopez AD, Lopukhov PD, Lunevicius R, Madadin M, Magdeldin S, El Razek HMA, Majeed A, Maleki A, Malekzadeh R, Manafi A, Manafi N, Manamo WA, Mansourian M, Mansournia MA, Mantovani LG, Maroufizadeh S, Martini SMS, Mashamba-Thompson TP, Massenburg BB, Maswabi MT, Mathur MR, McAlinden C, McKee M, Meheretu HAA, Mehrotra R, Mehta V, Meier T, Melaku YA, Meles GG, Meles HG, Melese A, Melku M, Memiah PTN, Mendoza W, Menezes RG, Merat S, Meretoja TJ, Mestrovic T, Miazgowski B, Miazgowski T, Mihretie KMM, Miller TR, Mills EJ, Mir SM, Mirzaei H, Mirzaei HR, Mishra R, Moazen B, Mohammad DK, Mohammad KA, Mohammad Y, Darwesh AM, Mohammadbeigi A, Mohammadi H, Mohammadi M, Mohammadian M, Mohammadian-Hafshejani A, Mohammadoo-Khorasani M, Mohammadpourhodki R, Mohammed AS, Mohammed JA, Mohammed S, Mohebi F, Mokdad AH, Monasta L, Moodley Y, Moosazadeh M, Moossavi M, Moradi G, Moradi-Joo M, Moradi-Lakeh M, Moradpour F, Morawska L, Morgado-da-Costa J, Morisaki N, Morrison SD, Mosapour A, Mousavi SM, Muche AA, Muhammed OSS, Musa J, Nabhan AR, Naderi M, Nagarajan AJ, Nagel G, Nahvijou A, Naik G, Najafi F, Naldi L, Nam HS, Nasiri N, Nazari J, Negoi I, Neupane S, Newcomb PA, Nggada HA, Ngunjiri JW, Nguyen CT, Nikniaz L, Ningrum DNA, Nirayo YL, Nixon MR, Nnaji CA, Nojomi M, Nosratnejad S, Shiadeh MN, Obsa MS, Ofori-Asenso R, Ogbo FA, Oh IH, Olagunju AT, Olagunju TO, Oluwasanu MM, Omonisi AE, Onwujekwe OE, Oommen AM, Oren E, Ortega-Altamirano DDV, Ota E, Otstavnov SS, Owolabi MO, P A M, Padubidri JR, Pakhale S, Pakpour AH, Pana A, Park EK, Parsian H, Pashaei T, Patel S, Patil ST, Pennini A, Pereira DM, Piccinelli C, Pillay JD, Pirestani M, Pishgar F, Postma MJ, Pourjafar H, Pourmalek F, Pourshams A, Prakash S, Prasad N, Qorbani M, Rabiee M, Rabiee N, Radfar A, Rafiei A, Rahim F, Rahimi M, Rahman MA, Rajati F, Rana SM, Raoofi S, Rath GK, Rawaf DL, Rawaf S, Reiner RC, Renzaho AMN, Rezaei N, Rezapour A, Ribeiro AI, Ribeiro D, Ronfani L, Roro EM, Roshandel G, Rostami A, Saad RS, Sabbagh P, Sabour S, Saddik B, Safiri S, Sahebkar A, Salahshoor MR, Salehi F, Salem H, Salem MR, Salimzadeh H, Salomon JA, Samy AM, Sanabria J, Santric Milicevic MM, Sartorius B, Sarveazad A, Sathian B, Satpathy M, Savic M, Sawhney M, Sayyah M, Schneider IJC, Schöttker B, Sekerija M, Sepanlou SG, Sepehrimanesh M, Seyedmousavi S, Shaahmadi F, Shabaninejad H, Shahbaz M, Shaikh MA, Shamshirian A, Shamsizadeh M, Sharafi H, Sharafi Z, Sharif M, Sharifi A, Sharifi H, Sharma R, Sheikh A, Shirkoohi R, Shukla SR, Si S, Siabani S, Silva DAS, Silveira DGA, Singh A, Singh JA, Sisay S, Sitas F, Sobngwi E, Soofi M, Soriano JB, Stathopoulou V, Sufiyan MB, Tabarés-Seisdedos R, Tabuchi T, Takahashi K, Tamtaji OR, Tarawneh MR, Tassew SG, Taymoori P, Tehrani-Banihashemi A, Temsah MH, Temsah O, Tesfay BE, Tesfay FH, Teshale MY, Tessema GA, Thapa S, Tlaye KG, Topor-Madry R, Tovani-Palone MR, Traini E, Tran BX, Tran KB, Tsadik AG, Ullah I, Uthman OA, Vacante M, Vaezi M, Varona Pérez P, Veisani Y, Vidale S, Violante FS, Vlassov V, Vollset SE, Vos T, Vosoughi K, Vu GT, Vujcic IS, Wabinga H, Wachamo TM, Wagnew FS, Waheed Y, Weldegebreal F, Weldesamuel GT, Wijeratne T, Wondafrash DZ, Wonde TE, Wondmieneh AB, Workie HM, Yadav R, Yadegar A, Yadollahpour A, Yaseri M, Yazdi-Feyzabadi V, Yeshaneh A, Yimam MA, Yimer EM, Yisma E, Yonemoto N, Younis MZ, Yousefi B, Yousefifard M, Yu C, Zabeh E, Zadnik V, Moghadam TZ, Zaidi Z, Zamani M, Zandian H, Zangeneh A, Zaki L, Zendehdel K, Zenebe ZM, Zewale TA, Ziapour A, Zodpey S, Murray CJL.

JAMA Oncol. 2019 Sep 27. doi: 10.1001/jamaoncol.2019.2996. [Epub ahead of print]

4.

Pooled Prevalence of NS5A Resistance-Associated Substitutions in Chronic HCV Genotype 3 Infection: A Study Based on Deposited Sequences in GenBank.

Sharafi H, Ghalamkari S, Hassanshahi A, Alavian SM.

Microb Drug Resist. 2019 Sep;25(7):1072-1079. doi: 10.1089/mdr.2018.0358. Epub 2019 Apr 25.

PMID:
31021305
5.

Performance of a rapid diagnostic test for screening of hepatitis C in a real-life prison setting.

Sharafi H, Poustchi H, Azimian F, Tamadoni B, Ramezani R, Gouya MM, Sheikh M, Hashemi F, Tashakorian M, Alasvand R, Alavian SM, Merat S.

J Clin Virol. 2019 Apr;113:20-23. doi: 10.1016/j.jcv.2019.02.005. Epub 2019 Feb 25.

PMID:
30825832
6.

Prevalence of hepatitis C virus NS5A resistance-associated substitutions in chronic infection with genotype 1: A pooled analysis based on deposited sequences in GenBank.

Sharafi H, Maleki S, Alavian SM.

Virus Res. 2019 Jan 2;259:54-61. doi: 10.1016/j.virusres.2018.10.014. Epub 2018 Oct 25.

PMID:
30401643
7.

Hepatitis C resistance to NS5A inhibitors: Is it going to be a problem?

Sharafi H, Alavian SM.

World J Hepatol. 2018 Sep 27;10(9):543-548. doi: 10.4254/wjh.v10.i9.543.

8.

Serum cytokines, adipokines and ferritin for non-invasive assessment of liver fibrosis in chronic liver disease: a systematic review.

Haghgoo SM, Sharafi H, Alavian SM.

Clin Chem Lab Med. 2019 Apr 24;57(5):577-610. doi: 10.1515/cclm-2018-0357. Review.

9.

Comment on 'Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study'.

Alavian SM, Sharafi H.

Eur J Gastroenterol Hepatol. 2018 Jul;30(7):807-808. doi: 10.1097/MEG.0000000000001124. No abstract available.

PMID:
29847527
10.

A facile PCR-RFLP method for genotyping of ITPA rs1127354 and rs7270101 polymorphisms.

Alavian SE, Sharafi H, Shirmast P, Alavian SM, Behnava B, Pouryasin M, Keshvari M, Pouryasin A.

J Clin Lab Anal. 2018 Sep;32(7):e22440. doi: 10.1002/jcla.22440. Epub 2018 Apr 16.

11.
12.

Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis.

Dolatimehr F, Karimi-Sari H, Rezaee-Zavareh MS, Alavian SM, Behnava B, Gholami-Fesharaki M, Sharafi H.

Daru. 2017 Apr 20;25(1):11. doi: 10.1186/s40199-017-0177-x. Review.

13.

Combination of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C Virus Genotype 1 Infection: Systematic Review and Meta-Analysis.

Rezaee-Zavareh MS, Hesamizadeh K, Behnava B, Alavian SM, Gholami-Fesharaki M, Sharafi H.

Ann Hepatol. 2017 March-April;16(2):188-197. doi: 10.5604/16652681.1231562. Review. No abstract available.

14.

Molecular Tracing of Hepatitis C Virus Genotype 1 Isolates in Iran: A NS5B Phylogenetic Analysis with Systematic Review.

Hesamizadeh K, Alavian SM, Najafi Tireh Shabankareh A, Sharafi H.

Hepat Mon. 2016 Nov 19;16(12):e42938. doi: 10.5812/hepatmon.42938. eCollection 2016 Dec. Review.

15.

A Simple PCR-RFLP Method for Genotyping of IFNL4 rs368234815 Polymorphism in Patients With Chronic Hepatitis C.

Pouryasin M, Sharafi H, Behnava B, Alavian SM, Keshvari M, Pouryasin A.

Lab Med. 2017 Feb;48(1):51-56. doi: 10.1093/labmed/lmw060. Epub 2017 Jan 4.

PMID:
28057801
16.

Combination of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C Virus Genotype 1 Infection: Systematic Review and Meta-Analysis.

Rezaee-Zavareh MS, Hesamizadeh K, Behnava B, Alavian SM, Gholami-Fesharaki M, Sharafi H.

Ann Hepatol. 2017 Mar - Apr;16(2):188-197. doi: 10.5604/16652681.1231577. Review.

17.
18.

The Distribution of Hepatitis C Virus Genotypes in Middle Eastern Countries: A Systematic Review and Meta-Analysis.

Ghaderi-Zefrehi H, Gholami-Fesharaki M, Sharafi H, Sadeghi F, Alavian SM.

Hepat Mon. 2016 Aug 23;16(9):e40357. eCollection 2016 Sep. Review.

19.

Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline.

Alavian SM, Hajarizadeh B, Bagheri Lankarani K, Sharafi H, Ebrahimi Daryani N, Merat S, Mohraz M, Mardani M, Fattahi MR, Poustchi H, Nikbin M, Nabavi M, Adibi P, Ziaee M, Behnava B, Rezaee-Zavareh MS, Colombo M, Massoumi H, Bizri AR, Eghtesad B, Amiri M, Namvar A, Hesamizadeh K, Malekzadeh R.

Hepat Mon. 2016 Aug 13;16(8):e40959. eCollection 2016 Aug. Review.

20.

Impact of IFNL4 rs12979860 and rs8099917 polymorphisms on response to Peg-Interferon-α and Ribavirin in patients with congenital bleeding disorder and chronic hepatitis C.

Keshvari M, Alavian SM, Behnava B, Pouryasin A, Craig JC, Sharafi H.

J Clin Lab Anal. 2017 Jul;31(4). doi: 10.1002/jcla.22063. Epub 2016 Oct 13.

21.

The high-diagnostic characteristics of HBsAg level in differentiation of hepatitis B clinical presentations: Myth or truth?

Sharafi H, Karimi-Sari H, Alavian SM.

Liver Int. 2017 Apr;37(4):620-621. doi: 10.1111/liv.13259. Epub 2016 Oct 24. No abstract available.

PMID:
27696618
22.

The Prevalence of Hepatitis C Virus Core Amino Acid 70 Substitution and Genotypes of Polymorphisms Near the IFNL3 Gene in Iranian Patients With Chronic Hepatitis C.

Kadjbaf D, Keshvari M, Alavian SM, Pouryasin A, Behnava B, Salimi S, Mehrnoush L, Karimi Elizee P, Sharafi H.

Hepat Mon. 2016 May 3;16(6):e37011. doi: 10.5812/hepatmon.37011. eCollection 2016 Jun.

23.

Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals.

Hesamizadeh K, Sharafi H, Rezaee-Zavareh MS, Behnava B, Alavian SM.

Hepat Mon. 2016 Apr 18;16(4):e37089. doi: 10.5812/hepatmon.37089. eCollection 2016 Apr. Review.

24.

The ITPA and C20orf194 Polymorphisms and Hematological Changes During Treatment With Pegylated-Interferon Plus Ribavirin in Patients With Chronic Hepatitis C.

Pouryasin M, Keshvari M, Sharafi H, Alavian SM, Behnava B, Alavian SE, Pouryasin A.

Hepat Mon. 2016 Feb 20;16(2):e35278. doi: 10.5812/hepatmon.35278. eCollection 2016 Feb.

25.

The Role of Polymorphisms Near the IL28B Gene on Response to Peg-Interferon and Ribavirin in Thalassemic Patients With Hepatitis C.

Behnava B, Sharafi H, Keshvari M, Pouryasin A, Mehrnoush L, Salimi S, Karimi Elizee P, Ghazimoghaddam M, Alavian SM.

Hepat Mon. 2016 Jan 23;16(1):e32703. doi: 10.5812/hepatmon.32703. eCollection 2016 Jan.

26.

Hepatitis A Virus and Hepatitis E Virus Seroprevalence Among Blood Donors in Tehran, Iran.

Hesamizadeh K, Sharafi H, Keyvani H, Alavian SM, Najafi-Tireh Shabankareh A, Sharifi Olyaie R, Keshvari M.

Hepat Mon. 2016 Jan 23;16(1):e32215. doi: 10.5812/hepatmon.32215. eCollection 2016 Jan.

28.

Appropriate Genotyping of Hepatitis B Virus in Iran.

Jazayeri SM, Sharafi H, Alavian SM.

Jundishapur J Microbiol. 2015 Oct 17;8(10):e23529. doi: 10.5812/jjm.23529. eCollection 2015 Oct. No abstract available.

29.

Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients.

Haj-Sheykholeslami A, Keshvari M, Sharafi H, Pouryasin A, Hemmati K, Mohammadzadehparjikolaei F.

World J Gastroenterol. 2015 Aug 7;21(29):8935-42. doi: 10.3748/wjg.v21.i29.8935.

30.

High Response Rate to Pegylated Interferon Alpha and Ribavirin Combination Therapy in Hemophilic Children with Chronic Hepatitis C; A Case-Control Study.

Mehrnoush L, Alavian SM, Sharafi H, Behnava B, Salimi S, Keshvari M.

Pediatr Hematol Oncol. 2015;32(6):399-405. doi: 10.3109/08880018.2015.1022915. Epub 2015 Jun 18.

PMID:
26086432
31.

Comparison of Serum Hepatitis B Virus DNA and HBsAg Levels Between HBeAg-Negative and HBeAg-Positive Chronic Hepatitis B Patients.

Keshvari M, Alavian SM, Sharafi H.

Jundishapur J Microbiol. 2015 Jan 14;8(3):e21444. doi: 10.5812/jjm.21444. eCollection 2015 Mar. Erratum in: Jundishapur J Microbiol. 2015 Dec;8(12):e31014.

32.

Distribution of Human Papillomavirus Genotypes in Liquid-based Samples; Abundance of HPV-53 in Tehran, Iran.

Pouryasin M, Sharafi H, Mousavi AS, Khodadad S, Marjani M, Jamshidi F, Pouryasin A.

Iran J Public Health. 2014 Aug;43(8):1159-60. No abstract available.

33.

Prevalence and trends of transfusion-transmitted infections among blood donors in Tehran, Iran from 2008 to 2013.

Keshvari M, Sharafi H, Alavian SM, Mehrabadi H, Zolfaghari S.

Transfus Apher Sci. 2015 Aug;53(1):38-47. doi: 10.1016/j.transci.2015.03.003. Epub 2015 Mar 12.

PMID:
25892591
34.

Can serum level of HBsAg differentiate HBeAg-negative chronic hepatitis B from inactive carrier state?

Sali S, Sharafi H, Alavian SH, Alavian SM, Etesam F, Salimi S, Merza MA, Keshvari M.

Diagn Microbiol Infect Dis. 2015 Jun;82(2):114-9. doi: 10.1016/j.diagmicrobio.2015.02.005. Epub 2015 Feb 20.

PMID:
25863529
35.

Efficacy of 24-week pegylated interferon alpha and ribavirin combination therapy in highly selected patients infected with hepatitis C virus genotype 1.

Sharafi H, Alavian SM, Keshvari M.

Hepat Mon. 2015 Jan 1;15(1):e24955. doi: 10.5812/hepatmon.24955. eCollection 2015 Jan.

36.

Efficacy of Prolonged Treatment With Pegylated Interferon (Peg-IFN) and Ribavirin in Thalassemic Patients With Hepatitis C Who Relapsed After Previous Peg-IFN-Based Therapy.

Sandoughdaran S, Alavian SM, Sharafi H, Behnava B, Salimi S, Mehrnoush L, Karimi Elizee P, Keshvari M.

Hepat Mon. 2015 Jan 13;15(1):e23564. doi: 10.5812/hepatmon.23564. eCollection 2015 Jan.

37.

The Impact of IFNL4 rs12979860 Polymorphism on Spontaneous Clearance of Hepatitis C; A Case-Control Study.

Sharafi H, Alavian SM, Behnava B, Pouryasin A, Keshvari M.

Hepat Mon. 2014 Oct 1;14(10):e22649. doi: 10.5812/hepatmon.22649. eCollection 2014 Oct.

38.

Differentiation of hepatitis B/hepatitis D coinfection and superinfection in asymptomatic blood donors: is it possible?

Keshvari M, Alavian SM, Sharafi H.

APMIS. 2014 Oct;122(10):1042. No abstract available.

PMID:
25356475
39.

Interferon-λ Genetic Variations and Hepatitis C: Yet to be Discovered.

Keshvari M, Sharafi H.

Hepat Mon. 2014 May 10;14(5):e19433. doi: 10.5812/hepatmon.19433. eCollection 2014 May. No abstract available.

40.

Alanine transaminase as a single marker is not reliable for selecting candidates of pegylated interferon and ribavirin treatment.

Sharafi H, Alavian SM, Keshvari M.

J Formos Med Assoc. 2015 Feb;114(2):195-6. doi: 10.1016/j.jfma.2014.04.002. Epub 2014 May 20. No abstract available.

41.

Comment on "No impact of interleukin-28B polymorphisms on spontaneous or drug-induced hepatitis delta virus clearance" by Ubaldo Visco-Comandini et al. [Dig. Liver Dis. 2014;46:348-52].

Keshvari M, Sharafi H, Alavian SM.

Dig Liver Dis. 2014 Aug;46(8):761-2. doi: 10.1016/j.dld.2014.03.015. Epub 2014 May 9. No abstract available.

PMID:
24815081
42.

Interferon alpha-2b therapy in chronic hepatitis delta.

Keshvari M, Alavian SM, Sharafi H, Karimi G, Gholami Fesharaki M.

Hepat Mon. 2014 Mar 1;14(3):e15729. doi: 10.5812/hepatmon.15729. eCollection 2014 Mar.

43.

Mysterious Linkages Between Hepatitis C Virus Genotypes, Interleukin-28B Genotypes and Viral Clearance- A Meta-Analysis.

Aalaei-Andabili SH, Behnava B, Salimi S, Sharafi H, Alavian SM.

Hepat Mon. 2014 Mar 2;14(3):e15895. doi: 10.5812/hepatmon.15895. eCollection 2014 Mar. Erratum in: Hepat Mon. 2014 Sep;14(9):e22648.

44.

How can we make decision for patients with chronic hepatitis B according to hepatitis B virus (HBV) DNA level?

Keshvari M, Alavian SM, Sharafi H.

Hepat Mon. 2014 Feb 5;14(2):e15285. doi: 10.5812/hepatmon.15285. eCollection 2014 Feb.

45.

How can the IL28B polymorphisms with linkage disequilibrium affect the natural course of hepatitis B inversely?

Keshvari M, Alavian SM, Sharafi H.

Liver Int. 2014 Aug;34(7):1127. doi: 10.1111/liv.12515. Epub 2014 Mar 24. No abstract available.

PMID:
24576012
46.

Association of -24CT, 1249GA, and 3972CT ABCC2 gene polymorphisms with methotrexate serum levels and toxic side effects in children with acute lymphoblastic leukemia.

Sharifi MJ, Bahoush G, Zaker F, Ansari S, Rafsanjani KA, Sharafi H.

Pediatr Hematol Oncol. 2014 Mar;31(2):169-77. doi: 10.3109/08880018.2013.870625.

PMID:
24552501
47.

What is the ethnicity-specific impact of genetic polymorphisms on the response to hepatitis C treatment in an admixed population of Brazilian patients?

Keshvari M, Alavian SM, Sharafi H.

Clinics (Sao Paulo). 2014 Feb;69(2):152. doi: 10.6061/clinics/2014(02)13. No abstract available.

48.

Can we include genetic variants with high linkage disequilibrium into a multiple logistic model?

Keshvari M, Sharafi H, Hajarizadeh B, Alavian SM.

Liver Int. 2014 Jul;34(6):964. doi: 10.1111/liv.12464. Epub 2014 Feb 7. No abstract available.

PMID:
24397313
49.

Distribution of IL28B Genotypes in Iranian Patients with Chronic Hepatitis C and Healthy Individuals.

Sharafi H, Pouryasin A, Alavian SM, Behnava B, Keshvari M, Salimi S, Mehrnoush L, Fatemi A.

Hepat Mon. 2012 Dec;12(12):e8387. doi: 10.5812/hepatmon.8387. Epub 2012 Dec 22.

50.

Development and Validation of a Simple, Rapid and Inexpensive PCR-RFLP Method for Genotyping of Common IL28B Polymorphisms: A Useful Pharmacogenetic Tool for Prediction of Hepatitis C Treatment Response.

Sharafi H, Pouryasin A, Alavian SM, Behnava B, Keshvari M, Mehrnoush L, Salimi S, Kheradvar O.

Hepat Mon. 2012 Mar;12(3):190-5. doi: 10.5812/hepatmon.849. Epub 2012 Mar 28.

Supplemental Content

Loading ...
Support Center